C4X Discovery acquires more drug discovery technology from insolvent MolPlex

13 July 2016

British company C4X Discovery (AIM: C4XD) has acquired a suite of advanced drug-discovery technologies from MolPlex under an insolvency agreement, it has been announced.

The new assets, which comprise a pioneering software-based system that combines state-of-the-art chemoinformatics, computational chemistry and artificial intelligence, will complement C4X’s existing platform, helping it to capitalize on the identification of high-value targets and generate drug candidates with greater clinical and commercial differentiation.

The MolPlex Technologies were originally developed at Newcastle University and have three aspects:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK